article thumbnail

Paving the Way for Virtual Trials in Neurology: A Fully Remote ALS Study in 2015

ActiGraph

Clinical trials, a vital component of the drug development process, were heavily disrupted because patients, often with weakened immune systems, could not visit hospitals and research sites. The COVID-19 pandemic has completely changed the way we think about clinical research and care.

article thumbnail

Paving the Way for Virtual Trials in Neurology: A Fully Remote ALS Study in 2015

ActiGraph

Clinical trials, a vital component of the drug development process, were heavily disrupted because patients, often with weakened immune systems, could not visit hospitals and research sites. The COVID-19 pandemic has completely changed the way we think about clinical research and care.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accelerate Clinical Development with Patient-Centric Digital Endpoints

ActiGraph

Drug development success rates have been on the decline since 2015. 1 The machinery of clinical development urgently needs some new oil. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases.

article thumbnail

Accelerate Clinical Development with Patient-Centric Digital Endpoints

ActiGraph

Drug development success rates have been on the decline since 2015. 1 The machinery of clinical development urgently needs some new oil. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases.

article thumbnail

Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and Europe

Digital Health Global

About Massive Bio: Massive Bio’s vision is to cover entire Pharma value chain with disruptive solutions to improve entire ecosystem from drug development to commercialization. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

article thumbnail

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

The announcement of the deal comes after Locemia has enjoyed a series of positive trial results for nasal glucagon in 2015; the most recent study data released showed the treatment proved safe for children , ages 4 to 17, with Type 1. Lilly has endured a steady string of failed drug development in recent years, according to the report.

article thumbnail

Asaya and medical cannabis care in the era of personalised medicine

Lloyd Price

A new medication is introduced to the market via legislation rather than through formal drug development practices (3); 3. We see a reversal of the trend towards single molecule drug development in favour of the use of raw botanical products containing complex chemovars. 6 May 2017. 3 Bonn-Miller M et al. 4 Reynolds P.